<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108548</url>
  </required_header>
  <id_info>
    <org_study_id>7657-CL-0001</org_study_id>
    <secondary_id>2013-004357-25</secondary_id>
    <nct_id>NCT02108548</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects</brief_title>
  <official_title>A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single and multiple
      ascending oral doses of ASP7657 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are healthy males aged 18 to 55 years of age (inclusive) (Parts 1 and 2, young
      cohorts) or the subject is an elderly healthy male or female subject aged 65 years or more
      (Part 2, elderly cohort).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Gastrointestinal safety findings
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and 2: Safety assessed by adverse events, vital signs, laboratory tests, electrocardiogram (ECGs), collagen and adenosine diphosphate (ADP)-induced platelet aggregation, and gastrointestinal (GI) safety assessments (Part 2 only)</measure>
    <time_frame>Up to Day 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Pharmacokinetics (PK) profile of ASP7657 after a single dose in plasma: AUCinf, AUClast, tlag, tmax, Cmax, t 1/2, Vz/F, CL/F</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf), AUC from the time of dosing to the last measurable concentration (AUClast), time prior to the time corresponding to the first measurable (nonzero) concentration (tlag), time of maximum plasma concentration (tmax), maximum plasma concentration (Cmax), terminal elimination half-life (t ½), apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F), and apparent total systemic clearance after single or multiple extravascular dosing (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: PK profile of ASP7657 in urine: Aelast, Aeinf, Aelast%, Aeinf%, CLr</measure>
    <time_frame>Day 1</time_frame>
    <description>Cumulative amount of drug excreted in urine from time of dosing up to the collection time of the last measurable concentration (Aelast), cumulative amount of drug excreted in urine from time of dosing extrapolated to time infinity (Aeinf), percent of drug dose excreted in urine from time of dosing up to the collection time of the last measurable concentration (Aelast%), percent of drug dose excreted in urine from time of dosing extrapolated to time infinity (Aeinf%), renal clearance (CLr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Pharmacodynamics (PD) profile of tumor necrosis factor alpha (TNF-α) in whole blood: maximum response (Rmax), area under the dose-response curve (AURC), and time to reach maximum response (tmax,R)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: PD in urine: Total urine volume over 24 hours</measure>
    <time_frame>Day -1 and Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PK profile of ASP7657 after first dose in plasma: tlag, tmax, Cmax and AUC from the time of dosing to 24 hours postdose (AUC24)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PK of ASP7657 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)</measure>
    <time_frame>Days 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PK profile of ASP7657 after last dose in plasma: AUC from the time of dosing to the start of the next dosing interval (AUCtau), tmax, Cmax, t ½, Vz/F, CL/F, Accumulation ration (Racc), peak-trough ratio (PTR)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of ASP7657 after last dose in urine: Aetau, (Aetau%), and CLr</measure>
    <time_frame>Day 14</time_frame>
    <description>Cumulative amount of drug excreted in urine from the time of dosing to the start of the next dosing interval (Aetau), percent of drug dose excreted in urine over the time interval between consecutive dosing (Aetau%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PD profile of plasma renin activity and aldosterone</measure>
    <time_frame>Days -1, 7, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PD of urine electrolytes: amount excreted over 24 hours (Ae24)</measure>
    <time_frame>Days -1 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Pharmacokinetics of ASP7657</condition>
  <condition>Pharmacodynamics of ASP7657</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Part 1: ASP7657 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: ASP7657 Single Ascending Dose - Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ASP7657 Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ASP7657 Multiple Ascending Dose Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP7657</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1: ASP7657 Single Ascending Dose</arm_group_label>
    <arm_group_label>Part 1: ASP7657 Single Ascending Dose - Food Effect</arm_group_label>
    <arm_group_label>Part 2: ASP7657 Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Part 2: ASP7657 Multiple Ascending Dose Elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 2: Naproxen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body mass index (BMI) range of 18.5 to 30.0 kg/m2, inclusive. The
             subject weighs at least 50 kg [screening]

          -  Subject agrees to undergo gastro-duodenoscopy (GDS) if needed (Part 1: in case of
             gastrointestinal (GI) complaints/positive fecal blood test; Part 2: all subjects)

        Exclusion Criteria:

          -  Subject has known or suspected hypersensitivity to ASP7657 or naproxen, or any
             components of the formulation used

          -  Subject has any of the liver function test above the upper limit of normal (ULN)

          -  Subject has any clinically significant history of allergic conditions (including drug
             allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated,
             asymptomatic, seasonal allergies at time of dosing)

          -  Subject has any history or evidence of any clinically significant cardiovascular, GI,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy

          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper
             respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day
             of admission

          -  Subject has any clinically significant abnormality

          -  Subject has a pulse &lt; 40 or &gt; 90 beats per minute (bpm); mean systolic blood pressure
             (SBP) &gt; 140 mmHg; mean diastolic blood pressure (DBP) &gt; 90 mmHg (measurements taken in
             triplicate after subject has been resting in supine position for 5 minutes; pulse will
             be measured automatically) at day -1. (For elderly subjects the following criteria
             apply: DBP &gt; 100 mmHg, SBP &gt; 160 mmHg [day of admission])

          -  Subject has a mean QT interval corrected for heart rate using Fridericia's formula
             (QTc(F)) of &gt; 430 ms (for males) and &gt; 450 ms (for females).

          -  Subject uses any prescribed or nonprescribed drugs (including nonsteroidal
             anti-inflammatory drugs (NSAIDs), anti-coagulants, vitamins, natural and herbal
             remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug
             administration, except for occasional use of paracetamol (up to 2 g/day)

          -  Subject has a history of smoking more than 10 cigarettes (or equivalent amount of
             tobacco) per day within 3 months prior to admission to the clinical unit.

          -  Subject has a history of drinking &gt; 21 units (males) or &gt; 14 units (females) of
             alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits
             [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit
             or the subject tests positive at screening or clinical admission for alcohol or drugs
             of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and
             opiates)

          -  Subject uses any drugs of abuse within 3 months prior to admission to the clinical
             unit

          -  Subject has significant blood loss, donated 1 unit (450 mL) of blood or more, or
             received a transfusion of any blood or blood products within 60 days or donated plasma
             within 7 days prior to clinic admission

          -  Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months
             prior to admission to the clinical unit regularly

          -  Subject has a positive serology test for hepatitis B surface antigen (HBsAg),
             anti-hepatitis A virus (HAV) (immunoglobulin [Ig]M), anti-hepatitis C virus (HCV) or
             anti-human immunodeficiency virus (HIV) 1+2

          -  Subject has a positive H.Pylori test at screening

          -  Subject has a positive fecal blood test at screening

          -  Subject participated in any interventional clinical study or has been treated with any
             investigational drugs within 90 days or 5 half-lives whichever is longer, prior to the
             initiation of screening

          -  Subject is an employee of the Astellas Group or Clinical Research Organization
             involved in the study

          -  Subject has a history of peptic ulceration or significant dyspepsia

          -  Subject uses concomitant medication associated with peptic ulceration, or presence of
             other risk factors for peptic ulceration

          -  Subject, if non-elderly, has endoscopic evidence of inflammation, ulceration, erosion,
             mucosal hemorrhage, or active bleeding in esophagus, stomach, pyloric channel or
             duodenum, and a mucosal grading scale score &gt; 2 for both stomach and duodenum at
             baseline visit (Part 2 healthy young male cohorts)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP7657</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>First in man</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

